Element Science

Develops wearable defibrillator for cardiac arrest

San Francisco, California, United States

About Element Science

Element Science focuses on developing health technology aimed at preventing sudden cardiac arrest. Its main product, Jewel®, is a wearable defibrillator that offers continuous protection for users at risk of cardiac events. Although Jewel® is not yet available for purchase in the U.S., it represents a significant advancement in medical devices. The company targets individuals who are at risk, which includes millions globally, and plans to generate revenue through the sale of these devices to consumers, healthcare providers, and insurance companies. Element Science distinguishes itself from competitors by not only prioritizing innovative medical solutions but also by fostering a diverse and inclusive workplace culture. The company's goal is to enhance the quality of life for individuals at risk of sudden cardiac arrest while also expanding its team and market presence.

San Francisco, CaliforniaHeadquarters
2013Year Founded
$178.1MTotal Funding
SERIES_CCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Stock Options
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
FSA (Flexible Spending Accounts)
HSA (Health Savings Account)
Employee Assistance Program through PEO

Risks

Delay in FDA approval could hinder Jewel® defibrillator's U.S. market entry.
Intensifying competition from companies like Zoll Medical may impact market share.
Semiconductor shortages could delay Jewel® device production and distribution.

Differentiation

Element Science's Jewel® defibrillator offers 24/7 protection for high-risk cardiovascular patients.
The company integrates machine learning with clinical-grade wearables for personalized patient care.
Element Science emphasizes DEIB, enhancing its workplace culture and innovation potential.

Upsides

Element Science raised $145.6M in Series C funding, supporting product development and expansion.
The global wearable medical device market is projected to grow at a 26.8% CAGR.
FDA's expedited approval process could accelerate Jewel® defibrillator's market entry.

Funding

Total raised$178.11 M
Latest valuation$728.00 M
StageSERIES_C